Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 44

Sort by

Sort Order Select

Journal Articles

Preclinical Efficacy and Biological Effects of Venetoclax and Ixazomib in Combination in Lymphoma Cells

Maria Cosenza, MS, Stefano Sacchi, MD, Samantha Pozzi, MD

Blood (2020) 136 (Supplement 1): 37–38.

https://doi.org/10.1182/blood-2020-134882

Published: 2020

Journal Articles

COO, MYC / BCL2 Status and R-IPI Define a Group of Poor Prognosis DLBCL Patients in a Real-World Clinical Setting

Stefania Bettelli, Raffaella Marcheselli, Samantha Pozzi, MD, Luigi Marcheselli, Robel Papotti, Elisa Forti, M. Christina Christina Cox, MD PhD, Arianna Di Napoli, Tamar Tadmor, MD, Antonino Maiorana, Valentina Donati, MD, Sara Galimberti, MD PhD, Stefano Sacchi, MD

Blood (2019) 134 (Supplement_1): 1617.

https://doi.org/10.1182/blood-2019-125689

Published: 2019

Journal Articles

Prognostication of Diffuse Large B-Cell Lymphoma By Lympho2Cx Assay and BCL2 and MYC Expression: Application in a Real Life Context of 154 Patients

Stefania Bettelli, Raffaella Marcheselli, Samantha Manfredini, Alessia Bari, MD, Samantha Pozzi, MD, M. Christina Christina Cox, MD PhD, Luigi Marcheselli, Arianna Di Napoli, Ilana Levy, MD, Elisa Forti, Tamar Tadmor, MD, Antonino Maiorana, Stefano Sacchi, MD

Blood (2018) 132 (Supplement 1): 5308.

https://doi.org/10.1182/blood-2018-99-117973

Published: 2018

Journal Articles

Ofatumumab Is Active and Safe in Patients with Relapsed/Refractory Splenic Marginal Zone Lymphoma (SMZL): Results from the Interim Analysis of an Italian Multicenter Phase 2 Study (MORE trial)

Lydia Scarfo, MD, Silvia Ferrari, Annamaria Maria Frustaci, Monica Tani, Samantha Pozzi, MD, Eloise Scarano, Maria Colia, Pamela Ranghetti, Maurilio Ponzoni, MD, Paola Ronchi, MD, Andres JM Ferreri, MD, Paolo Ghia, MD PhD

Blood (2018) 132 (Supplement 1): 4162.

https://doi.org/10.1182/blood-2018-99-113875

Published: 2018

Journal Articles

Combination of Momelotinib and Citarinostat Show Strong Synergistic Effect in Lymphoid Cell Lines Co-Targeting JAK2/STAT3 and HDAC6

Maria Cosenza, MS, Monica Civallero, PhD, Stefano Sacchi, MD, Samantha Pozzi, MD

Blood (2018) 132 (Supplement 1): 3506.

https://doi.org/10.1182/blood-2018-99-116468

Published: 2018

Journal Articles

Absolute Monocyte Count at Diagnosis Could Improve the Prognostic Role of Final FDG-PET in Diffuse Large B Cell Lymphoma Patients

Raffaella Marcheselli, PhD, Antonella Franceschetto, MD, Alessia Bari, MD, Luigi Marcheselli, MS, Tamar Tadmor, MD, Samantha Pozzi, MD, Ilana Levy, MD, Patrizia Pizzichini, MD, Daniela Prosperi, MD, Maria Christina Cox, MD, Rosaria D'Apollo, MD, Lucia Massi, MD, Napoleone Prandini, MD, Stefano Sacchi, MD

Blood (2017) 130 (Supplement 1): 1576.

https://doi.org/10.1182/blood.V130.Suppl_1.1576.1576

Published: 2017

Journal Articles

Ruxolitinib in Combination with Vorinostat Suppresses Tumor Growth and Alters the Metabolic Phenotype in Haematological Diseases

Monica Civallero, PhD, Maria Cosenza, MS, Sandra Marmiroli, MS, Samantha Pozzi, MD, Stefano Sacchi, MD

Blood (2017) 130 (Supplement 1): 5194.

https://doi.org/10.1182/blood.V130.Suppl_1.5194.5194

Published: 2017

Journal Articles

Momelotinib and Citarinostat: Co-Targeting JAK2/STAT3 and HDAC6 in Lymphoid Malignancies, a New Potential Therapeutic Combination

Maria Cosenza, MS, Monica Civallero, PhD, Stefano Sacchi, MD, Samantha Pozzi, MD

Blood (2017) 130 (Supplement 1): 5201.

https://doi.org/10.1182/blood.V130.Suppl_1.5201.5201

Published: 2017

Journal Articles

Prognostic Score Based on Clinical and Biochemical Surrogates of Disease Status in DLBCL Trated with Chemo-Immunotherapy

Luigi Marcheselli, Alessia Bari, MD, Samantha Pozzi, MD, Raffaella Marcheselli, M. Christina Cox, MD, Luca Baldini, Prof, Stefano Luminari, MD, Stefano Sacchi, MD

Blood (2014) 124 (21): 3027.

https://doi.org/10.1182/blood.V124.21.3027.3027

Published: 2014

Journal Articles

Preclinical Screening of the HDAC6 Inhibitor Rocilinostat (ACY-1215) Combined with Bendamustine in Lymphoma Cell Lines

Maria Cosenza, Monica Civallero, MS, PhD, Samantha Pozzi, MD, Luigi Marcheselli, Stefano Sacchi, MD

Blood (2014) 124 (21): 3124.

https://doi.org/10.1182/blood.V124.21.3124.3124

Published: 2014

Journal Articles

Romidepsin Synergizes with Lenalidomide in T Cell Lymphoma Cell Lines By Increasing Reactive Oxygen Species and Modulating PI3K/AKT and MAPK/ERK Signaling Pathways

Maria Cosenza, Monica Civallero, MS, PhD, Stefania Fiorcari, Samantha Pozzi, MD, Luigi Marcheselli, Stefano Sacchi, MD

Blood (2014) 124 (21): 1778.

https://doi.org/10.1182/blood.V124.21.1778.1778

Published: 2014

Journal Articles

Prognostic Role of Serum Albumin Level in DLBCL before and during the Rituximab Era. Retrospective GISL Study over 738 Cases

Luigi Marcheselli, Alessia Bari, MD, Samantha Pozzi, MD, Raffaella Marcheselli, Maria Christina Cox, MD, Luca Baldini, Prof, Stefano Luminari, MD, Stefano Sacchi, MD

Blood (2014) 124 (21): 5411.

https://doi.org/10.1182/blood.V124.21.5411.5411

Published: 2014

Journal Articles

Final Results Of a Phase II Study Of Lenalidomide In Combination With Rituximab For The Treatment Of Indolent Non Follicular Non Hodgkin Lymphoma

Stefano Sacchi, MD, Samantha Pozzi, MD, Marina Cesaretti, Luigi Marcheselli, MS, Gabriele Buda, MD, Antonio Lazzaro, MD, Luca Baldini, Francesco Di Raimondo, MD, Pellegrino Musto, MD, Alfonso Zaccaria, Giorgina Specchia, Umberto Vitolo, MD, Massimo Magagnoli, MD, Franco Silvestris, MD, Pier Paolo Fattori, MD, Patrizia Tosi, MD, Eliana Valentina Liardo, MD, Alessia Bari, MD, Angelo Michele Carella

Blood (2013) 122 (21): 4383.

https://doi.org/10.1182/blood.V122.21.4383.4383

Published: 2013

Journal Articles

Bendamustine, Low-Dose Dexamethasone, and Lenalidomide (BdL) For The Treatment Of Patients With Relapsed Multiple Myeloma Confirms Very Promising Results In a Phase I/II Study

Samantha Pozzi, MD, Stefania Badiali, MS, Alessandro Corso, MD, Pellegrino Musto, MD, Attilio Guarini, MD, Carla Minoia, MD, Donatella Vincelli, MD, Roberto Ria, MD, Luciano Masini, MD, Giovanni Quarta, MD, Massimo Gentile, MD, Carla Mazzone, MD, Antonio Palumbo, MD, Fortunato Morabito, MD, Stefano Sacchi, MD

Blood (2013) 122 (21): 3212.

https://doi.org/10.1182/blood.V122.21.3212.3212

Published: 2013

Journal Articles

Are Absolute Monocyte Count and The Lymphocyte-Monocyte Ratio (LMR) Valid Prognostic Factors In Classical Hodgkin Lymphoma? An Evaluation Based On Data From 1079 Patients

Stefano Sacchi, MD, Alessia Bari, MD, Tamar Tadmor, MD, Luigi Marcheselli, MS, Samantha Pozzi, MD, Eliana Valentina Liardo, MD, Angela Ferrari, MD, Caterina Stelitano, Paolo G Gobbi, Prof, Luca Baldini, Daniele Vallisa, MD, Emilio Iannitto, MD, Aaron Polliack, MD, Massimo Federico

Blood (2013) 122 (21): 1754.

https://doi.org/10.1182/blood.V122.21.1754.1754

Published: 2013

Journal Articles

Romidepsin and Lenalidomide Show a Synergistic Effect In T–Cell Lymphoma Cell Lines

Maria Cosenza, MS, Monica Civallero, MS, PhD, Stefania Fiorcari, MS, Samantha Pozzi, MD, Luigi Marcheselli, Eliana Valentina Liardo, MD, Alessia Bari, MD, Stefano Sacchi, MD

Blood (2013) 122 (21): 5148.

https://doi.org/10.1182/blood.V122.21.5148.5148

Published: 2013

Journal Articles

Absolute Monocyte Count At Diagnosis Is a Poor Prognostic Factor and Impacts Survival in Diffuse Large B-Cell Lymphoma: A Collaborative Multi-Center Study Involving 1026 Patients.

Tamar Tadmor, MD, Bari Alessia, MD, Stefano Sacchi, Luigi Marcheselli, Eliana Valentina Liardo, Irit Avivi, MD, Noam Benyamini, MD, Dina Attias, MD, Samantha Pozzi, MD, Massimo Federico, MD, Aaron Polliack, MD

Blood (2012) 120 (21): 2651.

https://doi.org/10.1182/blood.V120.21.2651.2651

Published: 2012

Journal Articles

Combination of NVP-BEZ235 and Enzastaurin on B-Cell Lymphoma Cell Lines: An Effective Therapeutic Strategy

Monica Civallero, Maria Cosenza, Samantha Pozzi, MD, Stefano Sacchi, MD

Blood (2011) 118 (21): 2719.

https://doi.org/10.1182/blood.V118.21.2719.2719

Published: 2011

Journal Articles

Secondary Leukemia After Non-Hodgkin Lymphoma: A Systematic Review and a Meta-Analysis

Raffaella Marcheselli, MS, Alessia Bari, MD, Eliana Valentina Liardo, MD, Luigi Marcheselli, MS, Samantha Pozzi, MD, Stefano Sacchi, MD

Blood (2011) 118 (21): 5192.

https://doi.org/10.1182/blood.V118.21.5192.5192

Published: 2011

Journal Articles

Targeting Bruton's Tyrosine Kinase As a Novel Approach to Inhibit Osteoclast Function in Multiple Myeloma

Homare Eda, MD, PhD, Loredana Santo, MD, Diana D. Cirstea, MD, Samantha Pozzi, MD, Miriam Canavese, PhD, Tyler A. Scullen, BA, Sonia Vallet, MD, Erica Evans, PhD, Juswinder Singh, PhD, Noopur S. Raje, MD

Blood (2011) 118 (21): 2882.

https://doi.org/10.1182/blood.V118.21.2882.2882

Published: 2011

NARROW

Preclinical Efficacy and Biological Effects of Venetoclax and Ixazomib in Combination in Lymphoma Cells

COO, MYC / BCL2 Status and R-IPI Define a Group of Poor Prognosis DLBCL Patients in a Real-World Clinical Setting

Prognostication of Diffuse Large B-Cell Lymphoma By Lympho2Cx Assay and BCL2 and MYC Expression: Application in a Real Life Context of 154 Patients

Ofatumumab Is Active and Safe in Patients with Relapsed/Refractory Splenic Marginal Zone Lymphoma (SMZL): Results from the Interim Analysis of an Italian Multicenter Phase 2 Study (MORE trial)

Combination of Momelotinib and Citarinostat Show Strong Synergistic Effect in Lymphoid Cell Lines Co-Targeting JAK2/STAT3 and HDAC6

Absolute Monocyte Count at Diagnosis Could Improve the Prognostic Role of Final FDG-PET in Diffuse Large B Cell Lymphoma Patients

Ruxolitinib in Combination with Vorinostat Suppresses Tumor Growth and Alters the Metabolic Phenotype in Haematological Diseases

Momelotinib and Citarinostat: Co-Targeting JAK2/STAT3 and HDAC6 in Lymphoid Malignancies, a New Potential Therapeutic Combination

Prognostic Score Based on Clinical and Biochemical Surrogates of Disease Status in DLBCL Trated with Chemo-Immunotherapy

Preclinical Screening of the HDAC6 Inhibitor Rocilinostat (ACY-1215) Combined with Bendamustine in Lymphoma Cell Lines

Romidepsin Synergizes with Lenalidomide in T Cell Lymphoma Cell Lines By Increasing Reactive Oxygen Species and Modulating PI3K/AKT and MAPK/ERK Signaling Pathways

Prognostic Role of Serum Albumin Level in DLBCL before and during the Rituximab Era. Retrospective GISL Study over 738 Cases

Final Results Of a Phase II Study Of Lenalidomide In Combination With Rituximab For The Treatment Of Indolent Non Follicular Non Hodgkin Lymphoma

Bendamustine, Low-Dose Dexamethasone, and Lenalidomide (BdL) For The Treatment Of Patients With Relapsed Multiple Myeloma Confirms Very Promising Results In a Phase I/II Study

Are Absolute Monocyte Count and The Lymphocyte-Monocyte Ratio (LMR) Valid Prognostic Factors In Classical Hodgkin Lymphoma? An Evaluation Based On Data From 1079 Patients

Romidepsin and Lenalidomide Show a Synergistic Effect In T–Cell Lymphoma Cell Lines

Absolute Monocyte Count At Diagnosis Is a Poor Prognostic Factor and Impacts Survival in Diffuse Large B-Cell Lymphoma: A Collaborative Multi-Center Study Involving 1026 Patients.

Combination of NVP-BEZ235 and Enzastaurin on B-Cell Lymphoma Cell Lines: An Effective Therapeutic Strategy

Secondary Leukemia After Non-Hodgkin Lymphoma: A Systematic Review and a Meta-Analysis

Targeting Bruton's Tyrosine Kinase As a Novel Approach to Inhibit Osteoclast Function in Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only